Navigation Links
Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements
Date:6/2/2008

xample newly diagnosed, is scheduled to start in 2009," explains Dr. Karl-Hermann Schlingensiepen, Chief Executive Officer of Antisense Pharma.

Literature

(1) Bogdahn, U. et al. "Results of a Phase IIb Active-controlled Study with AP 12009 for Patients with Recurrent or Refractory Anaplastic Astrocytoma", ASCO Annual Meeting, 2008, Abstract ID 2076

(2) Bogdahn, U. et al. "Targeted Therapy with AP 12009 in Recurrent or Refractory Glioblastoma Patients: Results of a Phase IIb Study", ASCO Annual Meeting, 2008, Abstract ID 2018

The Phase IIb study AP 12009-G004

The Phase IIb study AP 12009-G004 is an open-label, randomized, active-controlled, parallel-group dose-finding study to evaluate the efficacy and safety of two doses of AP 12009 in adult patients with recurrent or refractory high-grade glioma. Efficacy endpoints were tumor response assessed by central blinded MRI reading and survival. At 29 international clinical centers, 134 evaluable patients (39 with anaplastic astrocytoma, AA, WHO grade III and 95 with glioblastoma, GBM, WHO grade IV) have been randomized to three arms: AP 12009 10 mM, AP 12009 80 mM and standard chemotherapy (Temozolomide or PCV) as an active control. AP 12009 was administered intratumorally via one catheter as continuous high-flow microperfusion over a 7-day period every other week for up to 6 months on an outpatient treatment basis. Tumor response was assessed according to Macdonald criteria. Post-study follow-up for survival, long-term tumor response, and safety is still ongoing. Analysis of the core phase is completed.

High-Grade Glioma

Anaplastic astrocytoma and glioblastoma are the two most common forms of primary brain tumors, a diagnosis with high unmet medical need. Adults as well as children may be affected, although the age peak is at 45-65 years. Current therapies comprise surgery, radiation and/or chemotherapy. Despite recent advances, the prognosis for these patients is still po
'/>"/>

SOURCE Antisense Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
4. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
5. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
6. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
7. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
8. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
9. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
10. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
11. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... new market research report is available ... Market for Hospital-Acquired Infection Control (Sterilization, ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... healthcare-associated infections (HAIs), demand has increased ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces that ... its catalogue: The Impact of Healthcare ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html The ... is complex legislation that affects virtually every aspect ... are beginning to take effect now. IVD manufacturers ...
(Date:8/20/2014)... , Aug. 20, 2014 ... report is available in its catalogue: ... France, Key Trends and Opportunities to 2018 ... Synopsis The report provides in depth ... French personal accident and health insurance segment, ...
Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
... - Biovest,International, Inc. (OTCBB: BVTI), a majority owned ... 2007 blinded interim data from the start of ... for Non-Hodgkin's,lymphoma (NHL) from September 2000 through June ... data that has been made available,to the Company ...
... at the 11th International Myeloma Workshop -, NORTH ... -- The International Myeloma Foundation (IMF) --,supporting research ... families, researchers and physicians -- today,said that updated ... Greece demonstrate improved survival for a wide,range of ...
Cached Medicine Technology:Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 2The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 3The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 4
(Date:8/20/2014)... In its latest blog post, A Forever ... gets clients off to a great start and gives them ... highlighting an important and possibly life-changing – perhaps even life-saving ... to understand the insidious nature of drug abuse: it doesn’t ... abuse targets a certain socioeconomic group, such as inner-city youth ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 The ... that Munira Lokhandwala, DDS, FAGD of Starbrite Dental in ... the AGD 2014 Annual Meeting & Exhibits, which took ... Award is presented to dentists who seek to provide ... profession. To earn this prestigious honor, Dr. Lokhandwala completed ...
(Date:8/20/2014)... straight women are much more likely to seek treatment ... new study finds. Researchers examined data gathered from ... took part in polls in 2002 and 2006-2010, conducted ... study. In the first poll, 13 percent of ... This ranged from getting advice from doctors to more ...
(Date:8/20/2014)... August 20, 2014 Transrectal ultrasound guided biopsy is ... reports have suggested that the number of risks associated ... population-based study, Swedish researchers found that six percent of ... tract infection within 30 days after having a prostate ... five years, reports The Journal of Urology . ...
(Date:8/20/2014)... August 20, 2014 According to an ... August 7 in the multicounty litigation (MCL) case pending ... DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), nearly 350 ... been dismissed without prejudice. The cases enumerated in the ... being resolved.” The Rottenstein Law Group LLP, a national ...
Breaking Medicine News(10 mins):Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Fremont Dentist Receives Prestigious AGD Fellowship Award 2Health News:White Women More Likely to Seek Fertility Treatment: Report 2Health News:Severe infections with hospitalization after prostate biopsy rising in Sweden 2Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2
... disparities in longevity still tied to geography, race and income, ... who smoke, have high blood pressure, high blood sugar and ... average of four years, a new study finds. , In ... while women could be shaving 4.1 years off their lives, ...
... ... of the survivors of the earthquake in Haiti. The Grand Canyon University community has donated ... disaster struck on January 12, 2010. , ... Phoenix, AZ (PRWEB) March 23, 2010 -- Grand Canyon University,s Compassion ...
... ... expanded its continuum of care with a new licensed assisted living center. Under the direction ... a week. The center,s dedicated nurses and aides provide care and support to residents, helping ... ...
... a Preferred Partner to Genesis Rehab Services. , ... , , ... ... Being named a Preferred Partner means that Genesis Rehab ...
... BRISBANE, Calif. , March 23 InterMune, Inc. ... Authorization Application (MAA), submitted on March 2 seeking ... (IPF) in adults, was validated by the European Medicines Agency ... the application is complete and that the review process will ...
... ... Software-as-a-Service Model , ... (PRWEB) March 23, 2010 -- Healthmaster®, the worldwide leader in electronic medical record software ... their HealthOffice® Software-as-a-Service (Saas) platform in Online Tech’s SAS-70 certified data centers . ...
Cached Medicine News:Health News:Healthy Living Adds Years to Life 2Health News:Healthy Living Adds Years to Life 3Health News:Healthy Living Adds Years to Life 4Health News:Grand Canyon University (GCU) Creates Special Relief Fund and Raises Money for Haiti Earthquake Survivors 2Health News:Classic Residence by Hyatt at Teaneck Opens Licensed Assisted Living Center 2Health News:ReGear Life Sciences Named Preferred Partner to Genesis Rehab Services 2Health News:ReGear Life Sciences Named Preferred Partner to Genesis Rehab Services 3Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 2Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 3Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 4Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 5Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 6Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 7Health News:Online Tech and Healthmaster Sign SaaS Hosting Agreement 2Health News:Online Tech and Healthmaster Sign SaaS Hosting Agreement 3
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... wavelength (532 nm and 940 nm) laser ... solution. This solid-state laser quickly and effectively ... vulgaris. VariLite offers the clinical versatility to ... deeper, larger vessels in a convenient, affordable ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
Medicine Products: